FDA Spinal Disc Draft Guidance Under Development; AAOS Weighs In
This article was originally published in The Gray Sheet
Executive Summary
FDA's planned draft guidance on preclinical and clinical trial design for spinal disc replacement systems might draw on a FDL-1proposed guidance developed by the American Association of Orthopaedic Surgeons
You may also be interested in...
J&J/DePuy Charité Artificial Spinal Disc Unanimously Backed By FDA Panel
Johnson & Johnson/DePuy Spine should collect two years of postmarket follow-up data on Charité artificial lumbar disc recipients, according to FDA's Orthopaedic & Rehabilitation Devices Panel
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.